<PAGE>
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 10-C
REPORT BY ISSUER OF SECURITIES QUOTED ON NASDAQ
INTERDEALER QUOTATION SYSTEM
FILED PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934 AND RULE 13a-17
OR 15d-17 THEREUNDER
LIPOSOME TECHNOLOGY, INC.
- --------------------------------------------------------------------------------
(Exact name of issuer as specified in charter)
960 HAMILTON COURT, MENLO PARK, CA 94025
- --------------------------------------------------------------------------------
(Address of principal executive offices)
Issuer's telephone number, including area code (415) 323-9011
---------------
I. CHANGE IN NUMBER OF SHARES OUTSTANDING
Indicate any change (increase or decrease) of five percent or more in the number
of shares outstanding:
1. Title of security
----------------------------------------------------
2. Number of shares outstanding before the change
-----------------------
3. Number of shares outstanding after the change
------------------------
4. Effective date of change
---------------------------------------------
5. Method of change: Specify method (such as merger, acquisition,
exchange, distribution, stock split, acquisition
of stock for treasury, etc.)
- --------------------------------------------------------------------------------
Give brief description of transaction
------------------------------------------
II. CHANGE IN NAME OF ISSUER
1. Name prior to change LIPOSOME TECHNOLOGY, INC.
-------------------------------------------------
2. Name after change SEQUUS PHARMACEUTICALS, INC.
----------------------------------------------------
3. Effective date of charter amendment changing name JUNE 26, 1995
-------------------
4. Date of shareholder approval of change, if required N/A
-----------------
Date June 26, 1995 /s/ DONALD J. STEWART, V.P. FINANCE
------------------------------- --------------------------------------
(OFFICER'S SIGNATURE AND TITLE)
